Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Lupin Australia Pty Limited

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (297)
ARTG (242)
Prescription medicine registration (23)

Date

2025 (18)
2024 (49)
2023 (48)
2022 (222)
2021 (8)
2020 (33)
2019 (21)
2018 (32)
2017 (11)
2016 (10)
2014 (27)
2013 (14)
2012 (2)
2011 (16)
2010 (19)
2009 (1)
2008 (21)
2007 (5)
2001 (1)
1991 (4)

Search

Sponsor content

562 result(s) found, displaying 191 to 200

PREGABALIN LUPIN pregabalin 20 mg/mL oral solution bottle Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
LANSOPRAZOLE ODT LUPIN lansoprazole 30 mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
LANSOPRAZOLE ODT LUPIN lansoprazole 15 mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESOMEPRAZOLE LAPL esomeprazole (as magnesium) 40 mg enteric-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESOMEPRAZOLE LUP esomeprazole (as magnesium) 20 mg enteric-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESOMEPRAZOLE LAPL esomeprazole (as magnesium) 20 mg enteric-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESOMEPRAZOLE LAPL esomeprazole (as magnesium) 40 mg enteric-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESOMEPRAZOLE LUPIN esomeprazole (as magnesium) 40 mg enteric-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESOMEPRAZOLE LUP esomeprazole (as magnesium) 40 mg enteric-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
ESOMEPRAZOLE LUPIN esomeprazole (as magnesium) 20 mg enteric-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Lupin Australia Pty Limited

Pages

First page
Previous page
…
Page 16
Page 17
Page 18
Page 19
Current page 20
Page 21
Page 22
Page 23
Page 24
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.